Polpharma Biologics has its own pipeline of biosimilar and novel therapeutics for out-licensing. We are focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars or novel therapeutics.
Our proprietary cell line development platform and highly efficient R&D workflows have set the stage for the development of seven biosimilar candidates, with one finishing phase III and a second starting phase I of clinical trials.
Novel Biologics Pipeline
New Biologic Entities (NBEs) are a new area of focus for Polpharma Biologics, in which the detailed process knowledge acquired through the development of biosimilars can be combined with the extensive discovery experience of the Utrecht site to develop these innovative therapies.